The endocannabinoid system: linking body weight, metabolic disorders and tobacco dependence

Treatment with the newly developed drug rimonabant has been found to help to reduce body weight and improve cardiovascular and metabolic risk factors. It has also been shown to help smokers to stop using tobacco without the weight gain often associated with cessation. Beat Lutz reports on the recently discovered body system that links obesity, metabolic disorders and smoking, and the potential of rimonabant as a therapeutic option to tackle these multiple cardiovascular risk factors.
Author: 
Attachment: 
Keywords: 
endocannabinoid system, rimonabant, THC, CB1 receptor, neurotransmitter, metabolic syndrome, weight, obesity, sanofi aventis